Relative bioavailability of Neoral versus Sandimmune in the presence of a P450IIIA and P-glycoprotein inhibitor

被引：9

作者：

Choc, MG ^{[1
]}

Mueller, EA

Robinson, WT

Kumle, A

Smith, HT

Charnick, SB

机构：

[1] Nova Pharmaceut Corp, E Hanover, NJ 07936 USA

[2] Novartis Pharma AG, Basel, Switzerland

来源：

TRANSPLANTATION PROCEEDINGS | 1998年 / 30卷 / 05期

关键词：

D O I：

10.1016/S0041-1345(98)00383-2

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：1664 / 1665

页数：2

共 6 条

[1] Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery [J].

Benet, LZ ;

Wu, CY ;

Hebert, MF ;

Wacher, VJ .

JOURNAL OF CONTROLLED RELEASE, 1996, 39 (2-3) :139-143

[2] CYCLOSPORINE DISPOSITION AND METABOLITE PROFILES IN RENAL-TRANSPLANT PATIENTS RECEIVING A MICROEMULSION FORMULATION [J].

KOVARIK, JM ;

VERNILLET, L ;

MUELLER, EA ;

FREIBURGHAUS, R ;

NIEDERBERGER, W ;

KUTZ, K .

THERAPEUTIC DRUG MONITORING, 1994, 16 (05) :519-525

[3]

Meinzer Armin, 1996, P259

[4]

REYMOND JP, 1988, PHARMACEUT RES, V5, P677, DOI 10.1023/A:1015939307478

[5] ENHANCED INTESTINAL-ABSORPTION OF CYCLOSPORINE IN RATS THROUGH THE REDUCTION OF EMULSION DROPLET SIZE [J].

TARR, BD ;

YALKOWSKY, SH .

PHARMACEUTICAL RESEARCH, 1989, 6 (01) :40-43

[6] DIFFERENTIATION OF ABSORPTION AND FIRST-PASS GUT AND HEPATIC-METABOLISM IN HUMANS - STUDIES WITH CYCLOSPORINE [J].

WU, CY ;

BENET, LZ ;

HEBERT, MF ;

GUPTA, SK ;

ROWLAND, M ;

GOMEZ, DY ;

WACHER, VJ .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (05) :492-497

← 1 →